Dear Dr. Stevens:

Please refer to your new drug application (NDA) dated June 12, 2015, received June 15, 2015, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Mycapssa (octreotide) delayed-release capsules, for oral use, 20 mg.

We acknowledge receipt of your amendment dated December 24, 2019, which constituted a complete response to our April 15, 2016, action letter.

This new drug application provides for the use of Mycapssa (octreotide) delayed-release capsules, for oral use, for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at
FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible via publicly available labeling repositories.

**CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling submitted on June 5, 2020, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved NDA 208232.” Approval of this submission by FDA is not required before the labeling is used.

**MARKET PACKAGE**

Please submit one market package of the drug product when it is available to the following address:

Jennifer Johnson  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 3114  
10903 New Hampshire Avenue  
Silver Spring, Maryland  

*Use zip code 20903 if shipping via United States Postal Service (USPS).*  
*Use zip code 20993 if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).*

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).
the claimed indication in pediatric patients unless this requirement is waived, deferred,
or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are
exempt from this requirement.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and
promotional labeling. For information about submitting promotional materials, see the
final guidance for industry *Providing Regulatory Submissions in Electronic and Non-
Electronic Format—Promotional Labeling and Advertising Materials for Human
Prescription Drugs.*

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials,
and the Prescribing Information, at the time of initial dissemination or publication,
accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.

Information and Instructions for completing the form can be found at FDA.gov.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA
(21 CFR 314.80 and 314.81).

If you have any questions, call Jennifer Johnson, Regulatory Health Project Manager, at
(301) 796-2194.

Sincerely,

{See appended electronic signature page}

Theresa E. Kehoe, M.D.
Director (Acting)
Division of General Endocrinology
Office of Cardiology, Hematology, Endocrinology, and
Nephrology
Center for Drug Evaluation and Research

---

3 For the most recent version of a guidance, check the FDA guidance web page at
https://www.fda.gov/media/128163/download.

4 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf

5 http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Patient Package Insert
  - Instructions for Use
- Carton and Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

THERESA E KEHOE
06/26/2020 07:26:52 AM